CanBas Co

CanBas Co Net Debt/FCF

The Net Debt to Free Cash Flow Ratio of CanBas Co (4575.T) as of Oct 18, 2026 is 1.16. In the previous year, Net Debt to Free Cash Flow Ratio was 0.51 — a change of 124.72% (higher).

Net Debt/FCF

1.16

YoY

124.72%

Last updated:

Net Debt to Free Cash Flow Ratio of CanBas Co is 2023 1.16 . Net Debt to Free Cash Flow Ratio of CanBas Co was 2022 0.51 . It decreases by 124.72% higher compared to the previous year.

The CanBas Co Net Debt/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/FCF
Date
Net Debt/FCF
Jan 1, 2016
1.89 JPY
Jan 1, 2017
2.84 JPY
Jan 1, 2018
1.09 JPY
Jan 1, 2019
1.99 JPY
Jan 1, 2020
0.66 JPY
Jan 1, 2021
0.59 JPY
Jan 1, 2022
0.51 JPY
Jan 1, 2023
1.16 JPY
The CanBas Co Net Debt/FCF history
YEARNet Debt/FCFYoY
1.16+124.72%
0.51-12.45%
0.59-10.30%
0.66-67.13%
1.99+83.45%
1.09-61.71%
2.84+49.98%
1.89+73.62%
1.09—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CanBas Co Stock analysis

What does CanBas Co do? CanBas Co Ltd is a biotechnology company based in Numazu-shi, Japan, operating within the healthcare sector. The company has a small team of 12 employees and went public on September 17, 2009, with its ticker listed as 4575.T and ISIN JP3244570002. Its primary focus is on anticancer drug discovery research, which includes developing drug discovery concepts, selecting candidate compounds through method-based approaches, conducting simple animal studies, and analyzing basic data on anticancer drug candidates entering development. Additionally, CanBas engages in early clinical development activities, such as preclinical studies required before submitting applications for clinical trials and conducting the initial phases of clinical trials. The company maintains a website at https://www.canbas.co.jp/ for further information. CanBas operates as a private entity with a minimal workforce, emphasizing research and development in the early stages of anticancer drug development. It does not provide details on specific products, acquisitions, or financial figures beyond its IPO date and employee count. The company's headquarters are located in Numazu-shi, Shizuoka Prefecture, Japan, and it is listed on the Tokyo Stock Exchange. Its operations are centered around foundational research in oncology, aiming to contribute to the discovery and development of new anticancer treatments. CanBas Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CanBas Co stock

Net Debt to Free Cash Flow Ratio of CanBas Co is 1.16 in 2023.

Net Debt to Free Cash Flow Ratio of CanBas Co changed from 0.51 to 1.16, representing a 124.72% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Free Cash Flow Ratio CanBas Co since 2006 – with annual values, charts, and detailed analysis.

Net Debt/FCF indicates how many years it would take to repay net debt using free cash flow. Lower ratios suggest faster deleveraging potential.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Free Cash Flow Ratio's CanBas Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — CanBas Co

All Key Metrics — CanBas Co